Xu Hui, Zhang Fengxia, Gao Xiaokang, Zhou Qiwang, Zhu Linhai
Department of General Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Front Oncol. 2022 Aug 15;12:968306. doi: 10.3389/fonc.2022.968306. eCollection 2022.
Breast cancer has a marked recurrence and metastatic trait and is one of the most prevalent malignancies affecting women's health worldwide. Tumor initiation and progression begin after the cell goes from a quiescent to an activated state and requires different mechanisms to act in concert to regulate t a specific set of spectral genes for expression. Cancer stem cells (CSCs) have been proven to initiate and drive tumorigenesis due to their capability of self-renew and differentiate. In addition, CSCs are believed to be capable of causing resistance to anti-tumor drugs, recurrence and metastasis. Therefore, exploring the origin, regulatory mechanisms and ultimate fate decision of CSCs in breast cancer outcomes has far-reaching clinical implications for the development of breast cancer stem cell (BCSC)-targeted therapeutic strategies. In this review, we will highlight the contribution of BCSCs to breast cancer and explore the internal and external factors that regulate the fate of BCSCs.
乳腺癌具有显著的复发和转移特性,是全球影响女性健康的最常见恶性肿瘤之一。肿瘤的起始和进展始于细胞从静止状态转变为激活状态,并且需要不同的机制协同作用来调节一组特定的谱系基因的表达。癌症干细胞(CSCs)已被证明因其自我更新和分化能力而启动并驱动肿瘤发生。此外,CSCs被认为能够导致对抗肿瘤药物的耐药性、复发和转移。因此,探索乳腺癌中CSCs的起源、调控机制以及最终命运决定对于开发针对乳腺癌干细胞(BCSCs)的治疗策略具有深远的临床意义。在这篇综述中,我们将重点介绍BCSCs对乳腺癌的贡献,并探讨调节BCSCs命运的内部和外部因素。